Watch CBSN
/
J&J
SAE
the U.S. National Institutes for Health
NIH
Operation Warp Speed
the European Commission
Pre
AstraZeneca
Oxford University
All Rights Reserved
CBS Interactive Inc.
No matching tags
No matching tags
No matching tags
No matching tags
Washington
U.S.
Argentina
Brazil
Chile
Colombia
Mexico
Peru
South Africa
U.K.
Japan
the United States
© 2020 AFP
"We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant," the company said in a statement.The pause means the enrollment system has been closed for the 60,000-patient clinical trial while the independent patient safety committee is convened.J&J said that serious adverse events (SAEs), such as accidents or illnesses, are "an expected part of any clinical study, especially large studies." Company guidelines allow them to pause a study to determine if the SAE was related to the drug in question and whether to resume study.The J&J Phase 3 trial had started recruiting participants in late September, with a goal of enrolling up to 60,000 volunteers across more than 200 sites in the U.S. and around the world, the company and the U.S. National Institutes for Health (NIH), which is providing funding, said.
As said here by CBS News